Table 1.
Baseline demographic and clinical characteristics of ASCVD patients
| Characteristics | All patients
|
Filled high-intensity statins in all first four quarters
|
With >50% LDL-C reduction at 12-month follow-up
|
With LDL-C <70 mg/dL at 12-month follow-up
|
With LDL-C <100 mg/dL at 12-month follow-up
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | |
| Number of patients | 128,017 | 100 | 6,044 | 4.7 | 865 | 8.4* | 3,556 | 19.9* | 9,636 | 53.8* |
| Mean age (SD), mediana | 59 (13) | 58 | 55 (10) | 55 | 60 (11) | 59 | 60 (12) | 59 | 60 (12) | 59 |
| Female | 55,136 | 43.1 | 1,351 | 22.4 | 281 | 32.5 | 1,111 | 31.2 | 3,568 | 37.0 |
| Geographic region | ||||||||||
| Northeast | 31,179 | 24.4 | 1,163 | 19.2 | 354 | 40.9 | 1,367 | 38.4 | 3,978 | 41.3 |
| Midwest | 49,979 | 39.0 | 2,503 | 41.4 | 189 | 21.9 | 865 | 24.3 | 2,215 | 23.0 |
| South | 23,450 | 18.3 | 1,285 | 21.3 | 199 | 23.0 | 734 | 20.6 | 1,967 | 20.4 |
| West | 23,409 | 18.3 | 1,093 | 18.1 | 123 | 14.2 | 590 | 16.6 | 1,476 | 15.3 |
| Insurance plan type | ||||||||||
| HMO | 41,398 | 32.3 | 1,585 | 26.2 | 433 | 50.1 | 1,690 | 47.5 | 4,786 | 49.7 |
| PPO | 80,762 | 63.1 | 4,056 | 67.1 | 398 | 46.0 | 1,717 | 48.3 | 4,501 | 46.7 |
| Others | 5,857 | 4.6 | 403 | 6.7 | 34 | 3.9 | 149 | 4.2 | 349 | 3.6 |
| Type of ASCVD** | ||||||||||
| ACS | 26,887 | 21.0 | 3,873 | 64.1 | 298 | 34.5 | 1,233 | 34.7 | 2,564 | 26.6 |
| CHD | 71,884 | 56.2 | 4,473 | 74.0 | 599 | 69.3 | 2,364 | 66.5 | 6,044 | 62.7 |
| ACD | 22,311 | 17.4 | 511 | 8.5 | 90 | 10.4 | 431 | 12.1 | 1,276 | 13.2 |
| PAD | 23,457 | 18.3 | 123 | 2.0 | 93 | 10.8 | 439 | 12.4 | 1,552 | 16.1 |
| QCI, mean (SD), mediana | 0.86 (1.41) | 0.00 | 0.46 (1.05) | 0.00 | 0.86 (1.41) | 0.00 | 0.96 (1.44) | 0.00 | 0.94 (1.41) | 0.00 |
| Selected comorbidities of interest | ||||||||||
| Anxiety | 9,619 | 7.5 | 320 | 5.3 | 44 | 5.1 | 180 | 5.1 | 549 | 5.7 |
| Chronic kidney disease | 4,161 | 3.3 | 79 | 1.3 | 24 | 2.8 | 115 | 3.2 | 299 | 3.1 |
| Depression | 7,599 | 5.9 | 232 | 3.8 | 44 | 5.1 | 156 | 4.4 | 423 | 4.4 |
| Diabetes mellitus | 20,954 | 16.4 | 621 | 10.3 | 202 | 23.4 | 853 | 24.0 | 2,175 | 22.6 |
| Dyslipidemia | 45,208 | 35.3 | 1,727 | 28.6 | 488 | 56.4 | 1,440 | 40.5 | 4,038 | 41.9 |
| Hypertension | 60,121 | 47.0 | 2,113 | 35.0 | 480 | 55.5 | 1,850 | 52.0 | 5,006 | 52.0 |
| Obesity | 6,759 | 5.3 | 227 | 3.8 | 52 | 6.0 | 173 | 4.9 | 485 | 5.0 |
| Pain | 81,501 | 63.7 | 3,068 | 50.8 | 575 | 66.5 | 2,182 | 61.4 | 6,037 | 62.7 |
| Baseline lipid panel values‡,§ | ||||||||||
| ≥1 LDL-C value available | 26,653 | 20.8 | 775 | 12.8 | 865 | 100.0 | 1,843 | 51.8 | 5,319 | 55.2 |
| LDL-C <100 mg/dL | 8,279 | 31.1 | 137 | 17.7 | 89 | 10.3 | 977 | 53.0 | 2,518 | 47.3 |
| LDL-C <70 mg/dL | 1,803 | 6.8 | 35 | 4.5 | 5 | 0.6 | 418 | 22.7 | 637 | 12.0 |
| ≥1 HDL-C value available | 26,964 | 21.1 | 792 | 13.1 | 856 | 99.0 | 1,859 | 52.3 | 5,343 | 55.4 |
| HDL-C >40 mg/dL for males, >50 mg/dL for females | 17,655 | 65.5 | 437 | 55.2 | 539 | 63.0 | 1,106 | 59.5 | 3,380 | 63.3 |
| ≥1 triglyceride value available | 27,196 | 21.2 | 804 | 13.3 | 860 | 99.4 | 1,865 | 52.4 | 5,377 | 55.8 |
| Triglycerides <150 mg/dL | 17,757 | 65.3 | 459 | 57.1 | 500 | 58.1 | 1,158 | 62.1 | 3,480 | 64.7 |
| ≥1 total cholesterol value available | 27,292 | 21.3 | 808 | 13.4 | 860 | 99.4 | 1,870 | 52.6 | 5,386 | 55.9 |
| Total cholesterol <200 mg/dL | 14,703 | 53.9 | 307 | 38.0 | 244 | 28.4 | 1,359 | 72.7 | 3,640 | 67.6 |
| ≥1 non-HDL-C value available | 26,924 | 21.0 | 792 | 13.1 | 854 | 98.7 | 1,857 | 52.2 | 5,335 | 55.4 |
| Non-HDL-C <130 mg/dL | 9,780 | 36.3 | 153 | 19.3 | 108 | 12.6 | 1,001 | 53.9 | 2,701 | 50.6 |
| Baseline medications | ||||||||||
| Anti-claudication medications | 445 | 0.4 | 9 | 0.2 | 4 | 0.5 | 13 | 0.4 | 31 | 0.3 |
| Antidiabetic medications | 12,561 | 9.8 | 472 | 7.8 | 140 | 16.2 | 571 | 16.1 | 1,400 | 14.5 |
| Antihypertensive medications | 58,008 | 45.3 | 2,132 | 35.3 | 450 | 52.0 | 1,769 | 49.8 | 4,783 | 49.6 |
| Digoxin | 2,214 | 1.7 | 21 | 0.4 | 8 | 0.9 | 56 | 1.6 | 162 | 1.7 |
| Prescription antiplatelet and anticoagulant medications | 8,785 | 6.9 | 165 | 2.7 | 46 | 5.3 | 214 | 6.0 | 616 | 6.4 |
| Prescription omega 3 fatty acids | 689 | 0.5 | 31 | 0.5 | 9 | 1.0 | 23 | 0.7 | 69 | 0.7 |
Notes:
Data presented as mean (SD), median.
The denominator for 8.4% was patients with valid LDL-C values at both baseline and 12-month follow-up (n = 10,297); the denominator for 19.9% and 53.8% was patients with valid LDL-C values at 12-month follow-up (n = 17,915).
A patient could have multiple types of ASCVD on index date.
In cases where there was more than one eligible baseline laboratory result for the same lipid measure, the one closest to index date was used.
For each type of lipid panel value, the denominator for the percentage of patients with any given lipid level was the number of available patients with that lipid value.
Abbreviations: ACD, atherosclerotic cerebrovascular disease; ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; HMO, health maintenance organization; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; PPO, preferred provider organization; QCI, Quan-Charlson Comorbidity Index.